Browsing Tag
NASDAQ
801 posts
Why is Supermicro (NASDAQ: SMCI) stock surging more than 23%?
Super Micro Computer stock surged 23% after a margin surprise and $60 billion in orders. See what SMCI must prove on August 11.
Intel’s data-centre revenue jumped 22%. Why is Lip-Bu Tan cutting jobs there?
Intel is reducing roles inside the division benefiting most directly from surging demand for artificial-intelligence infrastructure, revealing how aggressively Lip-Bu Tan is pursuing efficiency across the semiconductor company.
Why Finward Bancorp shares jumped 21% and still traded below First Financial’s deal value
Finward Bancorp shares jumped to about $44.27 in extended trading after First Financial Bancorp announced an all-stock acquisition. The strategic logic centres on deposits and Chicago scale, but the final consideration will move with First Financial shares until closing.
Is PepsiCo stock a buy after recent weakness? Valuation improves but North America remains the test
PepsiCo’s share price has moved close to its 52-week low, lifting the dividend yield and lowering the earnings multiple. The valuation is increasingly attractive, but the investment case still depends on a gradual North American recovery.
Will Nano Dimension’s new leadership choose Infinite Epigenetics, Tang Capital or a third path?
Nano Dimension’s board reset puts $441.6 million of liquidity, asset sales and competing strategic paths under new leadership. The next move is decisive.
Palvella Therapeutics (NASDAQ: PVLA) rebounds 15% as investors reassess FDA path
Palvella Therapeutics is recovering from a sharp selloff as investors separate its advancing QTORIN rolling application from uncertainty surrounding a second indication.
Could fund secondaries turn Nasdaq Private Market into a broader liquidity platform?
Nasdaq Private Market’s NFS acquisition expands its private secondaries platform as fund liquidity demand grows across LP and GP transactions.
Tempus AI agrees to acquire Personalis in $1.5bn precision oncology deal built around a $46 floor price
Tempus AI to buy Personalis at $16.25 per share in a $1.5B stock-plus-optional-cash deal, with a $46 Tempus floor that gives Personalis the right to walk if breached.
Aehr Test Systems (NASDAQ: AEHR) stock jumps 20% as record backlog fuels growth outlook
Aehr Test Systems has returned to the centre of the semiconductor rally as investors price in record bookings, artificial-intelligence demand and extraordinary fiscal 2027 growth.
Mesoblast (ASX: MSB; Nasdaq: MESO) CEO invests A$2.73m as Ryoncil growth shifts focus to execution
Mesoblast Chief Executive Silviu Itescu has paid A$2.73 million to increase his ownership, adding an alignment signal as Ryoncil sales and late-stage programs reshape the company.